StockData
Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc. (HRMY) stock

HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.01+0.05 (+0.15%)

Close on Nov 17, 2026Market cap $1.92BP/E 10.7Yield –

Harmony Biosciences EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Harmony Biosciences's EV/EBITDA was 6.4× on Nov 11, 2026, against 6.8× a year earlier. Over the last 5 years it ranged from 4.8× to 37.4×, with a median of 8.7×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20266.4×−0.9
2025Dec 31, 20257.3×−2.6
2024Dec 31, 20249.9×+1.3
2023Dec 29, 20238.6×−22.5
2022Dec 30, 202231.1×−6.3
2021Dec 31, 202137.4×–

More Harmony Biosciences figures

See a number that looks wrong?